Research published in Antioxidants examines Vacrol® and S-Mix® as Carmed expands U.S. availability through Amazon and OneLavi.com. The post Carmed PharmaceuticalsResearch published in Antioxidants examines Vacrol® and S-Mix® as Carmed expands U.S. availability through Amazon and OneLavi.com. The post Carmed Pharmaceuticals

Carmed Pharmaceuticals Highlights Second Peer-Reviewed Study of Its Formulations

2026/06/10 05:00
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
Boca Raton, Florida (Newsworthy.ai) Tuesday Jun 9, 2026 @ 5:00 PM Eastern —

Carmed Pharmaceuticals, a research-driven company specializing in standardized carvacrol-based formulations, is highlighting the publication of a new peer-reviewed scientific study involving two of its flagship formulations, Vacrol® and S-Mix®.

The research, recently published in the journal Antioxidants, represents the second peer-reviewed publication in 2026 involving Carmed formulations, further reflecting the company’s long-term commitment to scientific investigation, formulation development, and academic collaboration.

The study evaluated Vacrol® and S-Mix® in a series of laboratory and preclinical experimental models, examining formulation characteristics, biological activity, and antimicrobial properties. Researchers concluded that the formulations demonstrated distinct biological profiles and warranted further mechanistic and translational investigation.

Building a Research-Driven Foundation

Unlike many wellness companies that focus primarily on product marketing, Carmed Pharmaceuticals has invested heavily in scientific collaboration and research surrounding its proprietary formulations.

The newly published paper follows a January 2026 peer-reviewed study published in Plants that also evaluated Carmed formulations in experimental models. Together, the publications contribute to a growing body of scientific literature examining standardized carvacrol-based formulations and their biological properties.

“Scientific inquiry has always been central to our philosophy,” said Mustafa Can, Founder of Carmed Pharmaceuticals. “We believe meaningful innovation requires ongoing research, independent evaluation, and a willingness to explore important scientific questions through rigorous study.”

The company emphasizes that the published research reflects scientific investigation into formulation science and biological mechanisms and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.

Supporting Long-Term Scientific Exploration

Carmed’s development approach focuses on standardized botanical formulations designed around reproducibility, analytical validation, and quality control.

The company collaborates with researchers, laboratories, healthcare institutions, and scientific advisors as part of its broader research ecosystem. These collaborations support ongoing investigation into botanical bioactives, formulation design, and potential mechanisms of action.

Expanding Availability in the United States

The publication comes as Carmed continues its expansion into the United States market.

Several Carmed formulations, coming soon to Amazon, are now available to U.S. consumers through OneLavi.com, including:

  •  Vacrol® Kids Spray – A carvacrol-based spray formulated to support upper respiratory wellness and microbial balance for children ages 4-11.

  • S-Mix® – A synergy-driven formulation designed to support immune function and healthy cellular activity.

  • Vacrol® Capsule – A standardized carvacrol formulation developed to support microbial balance and immune resilience.

  • Vacrol-M® Capsule – A multi-component botanical formulation designed to support immune function and respiratory wellness.

According to the company, expanding retail availability alongside continued scientific publication reflects Carmed’s broader strategy of combining research, quality-focused formulation development, and long-term brand building as it establishes its presence in the U.S. market.

About Carmed Pharmaceuticals

Carmed Pharmaceuticals is a research-driven company specializing in standardized, mechanism-based botanical formulations rooted in Anatolia’s rich botanical heritage. Integrating traditional plant knowledge with modern pharmaceutical technology, Carmed focuses on analytical validation, quality control, and reproducible formulation design.

Officially established in 2019 following years of focused research and development, the company operates with nearly 15 years of industry experience. All products are manufactured in accordance with Good Manufacturing Practice (GMP) principles and relevant regulatory standards, emphasizing safe production, environmental awareness, and continuous quality improvement.

Carmed develops standardized formulations designed to support preventive wellness, immune resilience, and cellular health through science-informed, quality-controlled processes.

Visit Carmed Pharmaceuticals website and visit them on Instagram.


This press release is distributed by the Newsworthy.ai™ Press Release Newswire – News Marketing Platform™. The reference URL for this press release is located here Carmed Pharmaceuticals Highlights Second Peer-Reviewed Study of Its Formulations.

The post Carmed Pharmaceuticals Highlights Second Peer-Reviewed Study of Its Formulations appeared first on citybuzz.

Market Opportunity
United Stables Logo
United Stables Price(U)
$1.0004
$1.0004$1.0004
0.00%
USD
United Stables (U) Live Price Chart

Predict & Trade to Win Rewards

Predict & Trade to Win RewardsPredict & Trade to Win Rewards

Guaranteed rewards with $500,000 prize pool

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

The Green Bay Packers Get Good News As Tucker Kraft Is Expected To Play Sunday

The Green Bay Packers Get Good News As Tucker Kraft Is Expected To Play Sunday

The post The Green Bay Packers Get Good News As Tucker Kraft Is Expected To Play Sunday appeared on BitcoinEthereumNews.com. Green Bay Packers tight end Tucker Kraft, who tweaked his knee during practice Thursday, is expected to play against Cleveland on Sunday. Copyright 2025 The Associated Press. All rights reserved. The Green Bay Packers, off to a sensational start, got some good news Saturday. NFL.com reported that Green Bay tight end Tucker Kraft is expected to play Sunday when the visiting Packers face Cleveland at noon. Kraft was listed as questionable on the injury report after tweaking his left knee in Thursday’s practice, then missing practice on Friday. “Yeah, hopefully he’ll be all right, but we’ll just kind of see how it goes,” Green Bay offensive coordinator Adam Stenavich said of Kraft. “Obviously, if anyone goes down that you have as a part of your game plan, you’ll have to adjust some things. So we’ll kind of see what happens with the injury report and everything like that, and what the trainers say, and we’ll make adjustments.” Kraft leads the Packers in receptions (eight), receiving yards (140) and receiving touchdowns (two) through two games. Kraft is coming off an enormous game in the Packers’ 27-18 Week 2 win over Washington. Kraft had a 57-yard reception on Green Bay’s first scoring drive in that contest when he ran vertical and was left uncovered. Kraft had an 8-yard touchdown catch in the fourth quarter that extended Green Bay’s lead to 24-10. “Oh, that boy’s nice,” Packers wideout Romeo Doubs said of Kraft. “Man, he is nice and it’s no surprise. You see it every day. Only difference is it’s gameday now.” Kraft’s most impressive play, though, might have been a 17-yard reception in the right flat midway through the second quarter. Kraft caught the ball just 5 yards downfield and safety Will Harris had a chance to make an immediate tackle. But…
Share
BitcoinEthereumNews2025/09/21 05:36
US Military Launches Retaliatory Strikes on Iran After Helicopter Downed

US Military Launches Retaliatory Strikes on Iran After Helicopter Downed

BitcoinWorld US Military Launches Retaliatory Strikes on Iran After Helicopter Downed In a significant escalation of tensions in the Middle East, the United States
Share
bitcoinworld2026/06/10 09:10
XRP Is Oversold On Every Time Frame, And This Could Be The Bullish Signal Everyone Is Waiting For

XRP Is Oversold On Every Time Frame, And This Could Be The Bullish Signal Everyone Is Waiting For

XRP is now oversold across all major time frames, signaling weakening momentum as its price continues to test key support levels. Crypto analyst Dark Defender revealed
Share
NewsBTC2026/06/10 09:00

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage